Business
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda
About this update from Vanda Pharmaceuticals Inc.
[{"type":"text","content":"\n Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market\n \n \n WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy® in overweight and obese adults.\n \n \n \n \n \n \n \n This study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg injection of Wegovy®, a dose that normally takes 9 weeks of titration to reach, succeeded and met its primary endpoint, with only 29.3% of tradipitant-treated participants (17/58) experiencing vomiting compared to 58.6% on placebo (34/58) (p=0.0016), representing a 50% relative reduction. The study also met the key secondary endpoint of the proportion of participants with vomiting and significant nausea at 22.4% in the tradipitant group (13/58) versus 48.3% on placebo (28/58) (p=0.0039).\n Tradipitant demonstrated a favorable safety profile consistent with previous studies with no new safety signals observed.\n \n \n \n \n \n \n Endpoint\n \n \n \n \n \n \n Placebo (N=58)\n \n \n \n \n \n \n Tradipitant (N=58)\n \n \n \n \n \n \n P-value\n \n \n \n \n \n \n \n Proportion with vomiting*\n \n \n \n \n 58.6% (34/58)\n \n \n \n \n 29.3% (17/58)\n \n \n \n \n 0.0016\n \n \n \n \n \n \n Proportion with vomiting and worst nausea ≥3**\n \n \n \n \n 48.3% (28/58)\n \n \n \n \n 22.4% (13/58)\n \n \n \n \n 0.0039\n \n \n \n \n \n *Primary endpoint**Key secondary endpoint, nausea of >= 3 denotes moderate or worse on a 0-5 point scale of severity\n \"These results demonstrate tradipitant's potential to mitigate GLP-1 induced nausea and vomiting which are key contributors of the 30-50% real-world discontinuation rates for GLP-1 agonists, often before therapeutic doses are reached,\" said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of Vanda. \"Tradipitant's effect in reducing nausea and vomiting could significantly improve GLP-1 agonist adherence enabling more people to receive the full therapeutic benefit.\"1...